

## Retraction: Sensitizing Estrogen Receptor-negative Breast Cancer Cells to Tamoxifen with OSU-03012, a Novel Celecoxib-derived Phosphoinositide-dependent Protein Kinase-1/Akt Signaling Inhibitor

Shu-Chuan Weng, Yoko Kashida, Samuel K. Kulp, Dasheng Wang, Robert W. Brueggemeier, Charles L. Shapiro, and Ching-Shih Chen



This article (1) has been retracted at the request of the editors. Following institutional review by the Ohio State University it was determined that Fig. 4A and B were intentionally falsified by Dr. Ching-Shih Chen. The authors regret any inconveniences or challenges resulting from the publication and subsequent retraction of this article.

A copy of this Retraction Notice was sent to the last known email addresses for the authors. Three authors (S.K. Kulp, R.W. Brueggemeier, and C.L. Shapiro) agreed to the retraction; the four remaining authors (S-C. Weng, Y. Kashida, D. Wang, and C-S. Chen) could not be located.

### Reference

1. Weng S-C, Kashida Y, Kulp SK, Wang D, Brueggemeier RW, Shapiro CL, et al. Sensitizing estrogen receptor-negative breast cancer cells to tamoxifen with OSU-03012, a novel celecoxib-derived phosphoinositide-dependent protein kinase-1/Akt signaling inhibitor. *Mol Cancer Ther* 2008;7: 800-8.

Published online April 1, 2019.

doi: 10.1158/1535-7163.MCT-19-0151

©2019 American Association for Cancer Research.